

ASTRAZENECA PLC  
Form 6-K  
September 01, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of September 2016

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue  
Cambridge Biomedical Campus  
Cambridge CB2 0AA  
United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-\_\_\_\_\_

01 September 2016 07:00 BST

ASTRAZENECA COMPLETES COMMERCIALISATION AGREEMENT WITH ASPEN FOR ANAESTHETICS PORTFOLIO

AstraZeneca today announced that it has completed\* the commercialisation agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, for rights to its global anaesthetics portfolio outside the US. The agreement covers seven established medicines - Diprivan (general anaesthesia), EMLA (topical anaesthetic) and five local anaesthetics (Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest). As AstraZeneca will retain a significant ongoing interest in the portfolio, the upfront payment (to be recognised in the third quarter of 2016), along with all future milestone and royalty payments, will be reported as Externalisation Revenue in the Company's financial statements.

\* With the exception of Ukraine and Zimbabwe, which are subject to separate closing

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: [www.astrazeneca.com](http://www.astrazeneca.com)

CONTACTS

Media Enquiries

Neil Burrows UK/Global +44 203 749 5637

Vanessa Rhodes UK/Global +44 203 749 5736

Karen Birmingham UK/Global +44 203 749 5634

Rob Skelding UK/Global +44 203 749 5821

Jacob Lund Sweden +46 8 553 260 20

Michele Meixell US +1 302 885 2677

Investor Relations

UK

Thomas Kudsk Larsen

+44 203 749 5712

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Craig Marks            Finance, Fixed Income, M&A            +44 7881 615 764

Nick Stone            Respiratory & Autoimmunity            +44 203 749 5716

Henry Wheeler            Oncology            +44 203 749 5797

Christer Gruvris            Infection & Neuroscience            +44 203 749 5711

US

Lindsey Trickett            Cardiovascular & Metabolic Diseases +1 240 543 7970

Mitchell Chan            Oncology            +1 240 477 3771

Toll-free            +1 866 381 7277

-ENDS-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 01 September 2016

By: /s/ Adrian Kemp  
Name: Adrian Kemp  
Title: Company Secretary